PUBLISHER: 360iResearch | PRODUCT CODE: 1464780
PUBLISHER: 360iResearch | PRODUCT CODE: 1464780
[190 Pages Report] The Antimalarial Drugs Market size was estimated at USD 1.67 billion in 2023 and expected to reach USD 1.76 billion in 2024, at a CAGR 5.88% to reach USD 2.50 billion by 2030.
Antimalarial drugs are pharmaceutical compounds designed to prevent and treat malaria, a life-threatening disease transmitted by an infected Anopheles mosquito bite. These drugs target the different life cycle stages of the Plasmodium parasites responsible for malaria, effectively reducing the disease's transmission and alleviating the symptoms in affected individuals. Antimalarial drugs' utility spans various contexts, from prophylactic usage in travelers to endemic regions to therapeutic interventions in diagnosed cases. The development and deployment of these medications are critical in global health efforts aimed at controlling, eliminating, and eradicating malaria, particularly in tropical and subtropical regions where the disease prevalence is highest. Rising incidence rates of malaria globally and the increasing support from global health organizations for malaria eradication programs are driving the growth of the antimalarial drugs market. However, the emergence of drug-resistant malaria strains is hindering the expanding antimalarial drugs market. Innovations in drug development and diagnostic tests in the area of antimalarial drugs offer lucrative growth opportunities for the market.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 1.67 billion |
Estimated Year [2024] | USD 1.76 billion |
Forecast Year [2030] | USD 2.50 billion |
CAGR (%) | 5.88% |
Drug Class: Widening use of artemisinin compounds owing to its effective results
Antifolate compounds, such as pyrimethamine and sulfadoxine, work by inhibiting folate synthesis within the malaria parasite, essential for its nucleic acid and protein production. These compounds are often combined to enhance their efficacy and prevent resistance. Artemisinin-based combination therapies (ACTs) are the cornerstone of modern malaria treatment and have significantly contributed to the reduction in malaria mortality rates worldwide. Derived from the plant Artemisia annua, artemisinin and its derivatives, such as artesunate, artemether, and dihydroartemisinin, are fast-acting and highly effective against Plasmodium falciparum. Aryl aminoalcohol compounds include quinine, mefloquine, and halofantrine, which are primarily effective against the erythrocytic stages of Plasmodium parasites. Despite their long history of use, the development of resistance and side effects have limited their use in favor of newer medications. They remain essential in certain contexts, particularly for treating multidrug-resistant strains of malaria. Endoperoxides include new developments designed to combat artemisinin resistance. These compounds, such as ozonide OZ439 (artefenomel), retain the vital peroxide bridge necessary for their antimalarial activity and offer a promising future for antimalarial treatment modalities with ongoing clinical trials. Quinoline methanol antimalarials, including mefloquine and lumefantrine, are effective against drug-resistant P. falciparum. Their mode of action includes interference with hemoglobin digestion within the parasite. Tetracyclines, such as doxycycline, are broad-spectrum antibiotics used as part of combination therapy for malaria, especially for treatment and prevention in areas with drug-resistant parasites. Due to their safety profile and cost-effectiveness, tetracyclines continue to see steady use in specific therapeutic scenarios.
Malaria Type: Increasing prevalence of plasmodium falciparum
Plasmodium falciparum is dangerous among the malaria parasites, often leading to severe malaria. This type of malaria requires fast-acting antimalarial drugs for treatment due to their high virulence and rapid progression. Artemisinin-based combination therapies (ACTs) are the recommended treatment for P. falciparum malaria worldwide. These include combinations such as artemether-lumefantrine and artesunate-amodiaquine. Other regimens, such as quinine combined with doxycycline or clindamycin, may be used in regions resistant to ACTs. Intravenous artesunate is preferred for severe malaria cases. Plasmodium knowlesi, initially known for infecting macaques, has emerged as a significant cause of human malaria in Southeast Asia. The treatment strategy for P. knowlesi is similar to that for Plasmodium falciparum due to its rapid lifecycle potentially leading to severe malaria. Artemisinin-based combination therapy (ACT) is effective. Plasmodium malariae causes a generally less severe form of malaria than P. falciparum. Chloroquine is typically adequate for treating P. malariae infections. Where chloroquine resistance is not a concern, this drug remains the first choice due to its effectiveness and low cost. Plasmodium ovale causes relapsing malaria due to dormant liver stages, similar to P. vivax. The treatment for P. ovale encompasses chloroquine for the blood-stage infection and a course of primaquine to clear the dormant liver stage and prevent relapse. This two-pronged approach ensures the elimination of the parasite from the bloodstream and the liver to prevent recurrence. Plasmodium vivax is notable for its ability to cause relapsing malaria due to dormant stages in the liver (hypnozoites). Treatment involves the use of chloroquine for the blood-stage infection paired with primaquine to eradicate the liver stage. Tafenoquine, a new alternative, offers similar benefits to primaquine but requires less frequent dosing, although it also requires screening for G6PD deficiency.
Regional Insights
In the Americas, the focus on antimalarial drugs predominantly revolves around countries with persistent malaria cases, such as Brazil, Colombia, and Peru in South America and some parts of Central America and the Caribbean. The market dynamics are characterized by active government intervention, including initiatives and funding to eradicate malaria. The Asia-Pacific region represents a highly diverse antimalarial drugs market due to varying malaria prevalence and healthcare infrastructure across countries such as India, China, and Indonesia. Factors such as a large at-risk population, climatic conditions conducive to mosquito breeding, and socio-economic disparities impact the market. Efforts toward malaria elimination and control have been intensified, with significant investments from governments and international bodies in healthcare systems, boosting the demand for antimalarial drugs. Issues of counterfeit drugs and drug resistance remain critical concerns. Stringent regulatory standards and a high level of awareness regarding malaria prevention guide consumer purchasing behavior in Europe. Recent research initiatives in the EU focus on vaccine development and the discovery of new antimalarial compounds. The EMEA region exhibits different market characteristics, with Africa having high malaria cases. The demand for antimalarial drugs in Sub-Saharan Africa remains high, driven by the prevalent use of drugs such as artemisinin-based combination therapies (ACTs). The Middle East experiences varied prevalence rates. The malaria elimination and control initiatives, especially in Africa, are expected to drive the antimalarial drugs market in the EMEA region.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Antimalarial Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Antimalarial Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Antimalarial Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alkem Laboratories, Alliance Pharma, Alvizia Health Care, Bayer AG, Cipla Inc., Dr. Reddy's Laboratories, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Glenmark Pharmaceuticals, Hikma Pharmaceuticals PLC, Ipca Laboratories Ltd., Lincoln Pharmaceuticals, Lupin Limited, Merck KGaA, Mylan, Novartis AG, Pfizer Inc., Sanofi Group, Strides Pharma Science Limited, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company, Teva Pharmaceuticals Industries Ltd., Zydus Group, and Zydus Lifesciences Ltd..
Market Segmentation & Coverage
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
1. What is the market size and forecast of the Antimalarial Drugs Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Antimalarial Drugs Market?
3. What are the technology trends and regulatory frameworks in the Antimalarial Drugs Market?
4. What is the market share of the leading vendors in the Antimalarial Drugs Market?
5. Which modes and strategic moves are suitable for entering the Antimalarial Drugs Market?